Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma
- PMID: 34003301
- PMCID: PMC10992072
- DOI: 10.1007/s00262-021-02965-w
Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma
Abstract
Backgound: Literature reports suggest that the host immune system may control Malignant Pleural Mesothelioma (MPM) growth, although its activity is limited by regulatory mechanisms. In this retrospective study, we analyzed the levels of pro-inflammatory (IL-1, IL-6, TNF), immune-regulatory (IL-10) and Th1/CTL-related cytokines (IL-12p70, IFN-γ) in the pleural exudate and their relationship with overall survival (OS) in MPM.
Methods: Cytokines were quantified by multiplexed immunoassay. Concentrations were dichotomized with respect to the median value. Correlation between cytokine level and OS was assessed using univariate (Kaplan-Meier curves) and multivariate (Cox regression) analyses.
Results: Regarding outcome, tumor histology, therapies undergone and IFN-γ were independent prognostic factors of OS in a 72 MPM training cohort. Notably, high concentrations of IFN-γ halved death probability (HR of high vs low IFN-γ concentration = 0.491, 95%CI 0.3-0.8, p = 0.007). Also in patients with epithelioid histology and those receiving at least one line of therapy, high IFN-γ level was an independent factor predictive of OS (HR of high vs low IFN-γ concentration were 0.497, p = 0.007 and 0.324, p = 0.006, respectively). However, these data were not confirmed in a 77 MPM validation cohort, possibly due to the low IFN-γ levels encountered in this population, and the heterogeneous distribution of disease stages between the training and the validation cohorts. None of the other cytokines showed any effect on survival.
Conclusions: High level of IFN-γ in pleural effusion may be associated with better survival in MPM patients and potentially serve as a prognostic biomarker. Larger prospective studies are needed to ascertain this hypothesis.
Keywords: Biomarker; Immune response; Interferon-gamma; Mesothelioma; Outcome; Pleural effusion.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
The author declares there is no conflict of interest.
Figures



Similar articles
-
The presence of pleural effusion is an independent prognostic factor in patients with malignant pleural mesothelioma.Sci Rep. 2025 Jan 2;15(1):392. doi: 10.1038/s41598-024-84108-6. Sci Rep. 2025. PMID: 39748018 Free PMC article.
-
Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.Lung Cancer. 2020 Jan;139:124-132. doi: 10.1016/j.lungcan.2019.11.013. Epub 2019 Nov 18. Lung Cancer. 2020. PMID: 31778960
-
V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.Mod Pathol. 2020 Feb;33(2):303-311. doi: 10.1038/s41379-019-0364-z. Epub 2019 Sep 19. Mod Pathol. 2020. PMID: 31537897 Free PMC article.
-
Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.Medicine (Baltimore). 2019 Apr;98(14):e14979. doi: 10.1097/MD.0000000000014979. Medicine (Baltimore). 2019. PMID: 30946324 Free PMC article.
-
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.J Clin Oncol. 2022 Feb 20;40(6):681-692. doi: 10.1200/JCO.21.01567. Epub 2022 Jan 5. J Clin Oncol. 2022. PMID: 34985934 Free PMC article. Review.
Cited by
-
IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells.Cancers (Basel). 2021 Aug 9;13(16):4011. doi: 10.3390/cancers13164011. Cancers (Basel). 2021. PMID: 34439164 Free PMC article.
References
-
- Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18:1261–1273. doi: 10.1016/S1470-2045(17)30446-1. - DOI - PubMed
-
- Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20:239–253. doi: 10.1016/S1470-2045(18)30765-4. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources